The SH2 domain of Bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype
Xw. Zhang et al., The SH2 domain of Bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype, BLOOD, 97(1), 2001, pp. 277-287
Bcr-Abl plays a critical role in the pathogenesis of chronic myelogenous le
ukemia (CML), It was previously shown that expression of Bcr-Abl in bone ma
rrow cells by retroviral transduction efficiently induces a myeloproliferat
ive disorder (MPD) in mice resembling human CML, This in vivo experimental
system allows the direct determination of the effect of specific domains of
Bcr-Abl, or specific signaling pathways, on the complex in vivo pathogenes
is of CML, In this report, the function of the SH2 domain of Bcr-Abl in the
pathogenesis of CML is examined using this murine model. It was found that
the Bcr-Abl SH2 mutants retain the ability to induce a fatal MPD but with
an extended latency compared with wild type (wt) Bcr-Abl. Interestingly, in
contrast to wt Bcr-Abl-induced disease, which is rapid and monophasic, the
disease caused by the Bcr-Abl SH2 mutants is biphasic, consisting of an in
itial B-lymphocyte expansion followed by a fatal myeloid proliferation, The
B-lymphoid expansion was diminished in mixing experiments with bcr-abl/Del
ta SHS and wt bcr-abl cells, suggesting that the Bcr-Abl-induced MPD suppre
sses B-lymphoid expansion. (C) 2001 by The American Society of Hematology.